Cancer-Specific Antibodies and Oncavert ™

According to the World Health Organization, the global incidence of cancer is expected to surge 57% over the next 20 years. Novel diagnostic and therapeutic tools are required to meet this critical health challenge. We have discovered that OncoVAX® treated patients generate cancer-specific antibodies that can be purified and scaled-up for commercial use. Despite the diversity observed across different cancer patients, these antibodies can cross-react with a surprising number of colon cancers and other carcinomas. We fully expect these highly unique antibodies can be commercialized for diagnostic and therapeutic benefit. More importantly, we intend to identify the cancer-specific targets of these antibodies to create Oncavert™, the first broad spectrum, preventive cancer vaccine.